

AstraZeneca R&D Pipeline: NCEs
25 July 2002

Gastrointestinal

NCE's

Compound	Mechanism	Areas under investigation	Phase	Estimated Filing	
				MAA	NDA
AR-H044277	Reversible acid pump inhibitor	Acid related GI disease	CT	>2004	>2004
AZD 3355 (Reflux inhibitor)	Inhibitor of transient lower esophageal sphincter relaxations (TLESR)	Gastroesophageal reflux disease (GERD)	CT	>2004	>2004
Rofleponide	Oral steroid with topical action	Inflammatory bowel disease	CT	>2004	>2004

Line Extensions

Nexium [®]	Proton pump inhibitor	Treatment of NSAID GI Side effects	DFL	1H 2003	1H 2003
Nexium [®]	Proton pump inhibitor	Parenteral formulation	DFL	1H 2003	1H 2003

Cardiovascular

NCE's

Crestor [™]	Statin	Hyperlipidemia	DFL	Filed	Filed
Exanta [™] (melagatran)	Thrombin inhibitor (s.c)	Prevention of VTE	DFL	3Q 2002	>2004
Exanta [™] (H376/95)	Thrombin inhibitor	Prevention of VTE	DFL	3Q 2002	2Q 2003
Exanta [™] (H376/95)	Thrombin inhibitor	Prevention of stroke in AF	DFL	2Q 2003	2Q 2003
Exanta [™] (H376/95)	Thrombin inhibitor	Treatment of VTE	DFL	1H 2003	2004
Exanta [™] (H376/95)	Thrombin inhibitor	Post Acute Coronary Syndrome	CT	>2004	>2004
AZD6140	P ₂ T antagonist	Arterial thrombosis	CT	>2004	>2004
AZ 242	PPAR agonist	Diabetes /Insulin resistance	CT	>2004	>2004
AZD7545	PDK inhibitor (anti-diabetic)	Diabetes	CT	>2004	>2004
AZD7009	Atrial Repolarisation Delaying Agent (ARDA)	Atrial Fibrillation	CT	>2004	>2004

Line Extensions

Atacand [®]	Angiotensin II antagonist	Hypertension outcomes (SCOPE study)	DFL	3Q 2002*	3Q 2002*
		CHF outcomes (CHARM study)	DFL	2H 2003	2H 2003
		Diabetic retinopathy	DFL	>2004	>2004

*submission for variation to existing label

NB. Paediatric programmes ongoing/planned: Atacand[®], Seloken[®]/Toprol-XL[®].

25 July 2002

CNS

NCE's

Compound	Mechanism	Areas under investigation	Phase	Estimated Filing	
				MAA	NDA
NXY-059	Free radical trapping agent	Stroke	CT	>2004	>2004
AR-A2	5HT _{1β} antagonist	Anxiety/Depression	CT	>2004	>2004
AZD1134	5HT _{1β} antagonist	Anxiety/Depression	CT	>2004	>2004
ZD 0947	K ⁺ channel opener	Overactive bladder	CT	>2004	>2004
AZD5106	NK-2 antagonist	Overactive bladder	CT	>2004	>2004

Line Extensions

Seroquel [®]	D ₂ /5HT ₂ antagonist	Granules	DFL	1H 2004	4Q 2002
Seroquel [®]	D ₂ /5HT ₂ antagonist	Sustained release	DFL	1Q 2003	1Q 2003
Seroquel [®]	D ₂ /5HT ₂ antagonist	Mania	DFL	1H 2003	1H 2003
Zomig [®]	5-HT _{1B/1D} receptor agonist	Nasal spray	DFL	Launched	Filed

Oncology

NCE's

Faslodex [™]	Oestrogen Receptor Antagonist	2 nd line Advanced breast cancer	DFL	1Q 2003	Launched
Faslodex [™]	Oestrogen Receptor Antagonist	1 st line Advanced breast cancer	DFL	>2004	>2004
Iressa [™]	Signal transduction inhibitor (Epidermal growth factor receptor tyrosine kinase inhibitor)	NSCLC and other solid tumours	DFL	4Q 2002*	Filed*
ZD 6126	Vascular targeting agent	Solid tumours	CT	>2004	>2004
AZD6474	Angiogenesis inhibitor (Vascular endothelial cell growth factor receptor tyrosine kinase inhibitor)	Solid tumours	CT	>2004	>2004
AZD2171	Angiogenesis inhibitor (Vascular endothelial cell growth factor receptor tyrosine kinase inhibitor)	Solid tumours and haematological malignancies	CT	>2004	>2004
AZD3409	Farnesyl-transferase inhibitor (FAR)	Solid tumours	CT	>2004	>2004
AZD0530	Non-receptor tyrosine kinase inhibitor	Solid tumours	CT	>2004	>2004

*US filing NSCLC combination 4Q 2002; EU filing NSCLC monotherapy and combination 4Q 2002

Line Extensions

Arimidex [®]	Aromatase inhibitor	Adjuvant Breast Cancer	DFL	Filed	Filed
Casodex [®]	Anti-androgen	Early Prostate Cancer	DFL	Launched	Filed
Zoladex [®]	LHRH agonist	Pre-menopausal Adjuvant Breast Cancer	DFL	Launched	1H 2003

25 July 2002

Respiratory and Inflammation

NCE's

Compound	Mechanism	Areas under investigation	Phase	Estimated Filing	
				MAA	NDA
Rofleponide palmitate	Intranasal steroid	Rhinitis	CT	2004	2004
AZD 4407	5-lipoxygenase inhibitor	COPD	CT	>2004	>2004
AZD 2315	Immuno modulator	Rheumatoid Arthritis*	CT	>2004	>2004
AZD9056	Ion channel blocker	Rheumatoid Arthritis*	CT	>2004	>2004
AZD8309	Chemokine receptor antagonist	Rheumatoid Arthritis*	CT	>2004	>2004
AZD7140	Chemokine receptor antagonist	Rheumatoid Arthritis*	CT	>2004	>2004

*First indication; use in other diseases eg. COPD under consideration.

Line Extensions

Symbicort [®] Turbuhaler [®]	Inhaled steroid/long-acting β_2 agonist	COPD	DFL	Filed	
Symbicort [®] Turbuhaler [®]	Inhaled steroid/long-acting β_2 agonist	Single therapy for asthma	DFL	1H 2003	
Symbicort [®] pMDI	Inhaled steroid/long-acting β_2 agonist	Asthma	DFL	2H 2003	2004
Oxis [®] Turbuhaler [®]	Long-acting β_2 agonist	COPD	DFL	Filed	
Oxis [®] Turbuhaler [®]	Long-acting β_2 agonist	Paediatrics Asthma	DFL	Approved	
Oxis [®] pMDI*	Long-acting β_2 agonist	Asthma / COPD	DFL	1H 2003	

Pain Control

NCE's

AZD3582	COX inhibiting nitric oxide donator	Acute /chronic nociceptive pain	CT	>2004	>2004
AZD4282 (oral glycine)	NMDA Antagonist	Neuropathic pain	CT	>2004	>2004

Line Extentions

Naropin [®]	Sodium channel blocker	Spinal anaesthesia	DFL	Filed	
----------------------	------------------------	--------------------	-----	-------	--

Infection

Line Extentions

Merrem [®]	Carbapenem antibiotic	Use in Neutropenics	DFL		>2004
Merrem [®]	Carbapenem antibiotic	Skin and soft tissue infections	DFL		4Q 2003

AstraZeneca R&D Pipeline: Discontinued Projects

GI

Compound	Mechanism
AR-H047108*	Reversible acid pump inhibitor

*Replaced with new CD AR-H044277

CNS

Compound	Mechanism
NAD 299 for anxiety and depression	5HT _{1A} antagonist
Zomig [®] for Adolescents	5-HT _{1B/1D} receptor agonist

Oncology

Compound	Mechanism
ZD 9331*	Thymidilate synthase inhibitor (oral)
ZD 9331*	Thymidilate synthase inhibitor (iv)

*Handed back to BTG 7 June 2002

Infection

Compound	Mechanism
AZD2563	Oxazolidinone antibiotic

Comments

As disclosure of compound information is balanced by the business need to maintain competitive advantage, some compound information has not been disclosed at this time.

Previous pipeline tables have displayed projects in the pre-clinical stage (prior to the selection of a candidate drug). The current table shows compounds in concept testing and development for launch only.

AstraZeneca is using a new terminology for the stage of development;

CT – concept testing, from CD nomination, through to phase I and phase II completion
DFL – development for launch, phase IIIa and phase IIIb activities conducted prior to filing

Other abbreviations;

CD – Candidate Drug
MAA - Marketing Authorisation Application (Europe)
NDA – New Drug Application (USA)